Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
about
Actions of bisphosphonates in animal models of breast cancerShould all adjuvant breast cancer patients receive a bisphosphonate?Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentRegulation of osteoclast differentiationA novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphomaThe role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeThe role of the bone microenvironment in skeletal metastasis.Does estrogen play a role in response to adjuvant bone-targeted therapies?Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cellsDifferential stem- and progenitor-cell trafficking by prostaglandin E2.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.The effect of risedronate on posterior lateral spinal fusion in a rat model.Optimal management of bone metastases in breast cancer patients.VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.Emerging drugs for the management of cancer treatment induced bone loss.Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.Mouse models of breast cancer metastasis to bone.Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.Aminobisphosphonate stimulates bone regeneration and enforces consolidation of titanium implant into a new rat caudal vertebrae model.Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.Local effect of zoledronic acid on new bone formation in posterolateral spinal fusion with demineralized bone matrix in a murine model.Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.Multimodal imaging of bone metastases: From preclinical to clinical applicationsEnoxacin and bis-enoxacin stimulate 4T1 murine breast cancer cells to release extracellular vesicles that inhibit osteoclastogenesis
P2860
Q24802119-B5D487DD-3D7D-4189-BE8C-7A64F50673AEQ24802817-534189C8-3FA5-464F-9E11-6F8F839A1D21Q25255562-80D59590-80A8-4DAD-A97E-2ECB6EF3A02AQ28593319-508A1AC4-23BA-4A48-AEA3-CBB20146C46CQ33705439-35EEA7F9-F5F7-4717-898D-10894F0C30B4Q34145863-B4AAB21B-FB4D-462E-A735-7BB605656A8DQ34613492-99861D7F-0E2E-433A-AA9E-9743F6289085Q35208717-5553FFA4-79C9-4CCE-9004-BAACE7EBF72AQ35550375-43715B3F-D910-4A57-BC7B-65210730E1B0Q35667196-BAA05020-064D-4593-9C22-35A41822C9C9Q36491430-DBB04CE6-CDF7-411A-8342-6B14F636DA8EQ36491529-08DC3920-3B0E-4E25-BF4E-AD52F6BEA2B5Q36491662-B89904D3-1FB1-428F-9C68-F4564FA9F153Q36711496-D37BC24E-C796-4770-8E2E-42574BDF90C8Q36759374-51B16106-111B-4459-879F-81AD4FEFE46EQ37312942-F9E671E3-BB23-4E17-9C87-8304729D4016Q37355487-FC6A4623-F2E9-446F-9F89-E259A20BF8F1Q37460998-CFC45A38-D839-47CB-B968-EEB5327A582CQ37727235-4AAF83DE-7FF2-4FD0-8C9B-91A3C580E980Q37845836-BA04D6F7-9380-404A-A8E1-CB7E78BA2E6CQ38019400-A69DA826-1516-4035-8A41-9FB1831A7284Q38867820-299970BF-1A33-4B2A-934A-A7442956C51AQ39138688-DA6869A6-769A-4661-911E-B58E597731DCQ42614194-7DCC1BD9-B720-4CF6-A01B-47F21BBF1AA0Q44973883-5116CB7C-0913-4021-B7C4-3623F284F0BCQ46832072-A623352C-68EE-4C3D-9C9B-A9CBF7AE96CCQ47904475-24171E83-F3DD-496B-87F7-76ECF78F8141Q52649233-A960A802-7DAC-4ABB-81EF-5A65E033C360Q56156782-5058708E-2409-4810-9292-4678DEF7D6C8Q58577597-037AE215-BE82-4324-B3B4-94B9F3B59F5E
P2860
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Preclinical studies with zoled ...... on the bone microenvironment.
@ast
Preclinical studies with zoled ...... on the bone microenvironment.
@en
Preclinical studies with zoled ...... on the bone microenvironment.
@nl
type
label
Preclinical studies with zoled ...... on the bone microenvironment.
@ast
Preclinical studies with zoled ...... on the bone microenvironment.
@en
Preclinical studies with zoled ...... on the bone microenvironment.
@nl
prefLabel
Preclinical studies with zoled ...... on the bone microenvironment.
@ast
Preclinical studies with zoled ...... on the bone microenvironment.
@en
Preclinical studies with zoled ...... on the bone microenvironment.
@nl
P2093
P1433
P1476
Preclinical studies with zoled ...... on the bone microenvironment.
@en
P2093
P356
10.1016/S0093-7754(01)90263-5
P433
P577
2001-04-01T00:00:00Z